CytoSorbents Launches VetResQ(TM) for U.S. Veterinary Market
Jan 20, 2017 09:00:00 (ET)
VetResQ Adds Advanced, First-In-Kind Blood Purification Treatment of Inflammatory Toxins to the U.S. Veterinary Market. Debuts at American College of Veterinary Emergency and Critical Care Post-Graduate Review Conference.
MONMOUTH JUNCTION, N.J., Jan. 20, 2017 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ: CTSO), a critical care immunotherapy leader using blood purification to treat deadly inflammation in critically-ill and cardiac surgery patients around the world, announces the marketing launch and commercial availability of the VetResQ(TM) sorbent cartridge for the United States veterinary market. VetResQ is a broad spectrum blood purification adsorber designed to help treat deadly inflammation and toxic injury in animals with critical illnesses such as septic shock, toxic shock syndrome, severe systemic inflammation, toxin-mediated diseases, pancreatitis, trauma, liver failure, and drug intoxication.
VetResQ is being showcased at the American College of Veterinary Emergency and Critical Care (ACVECC) Post-Graduate Review Course on January 20-21, 2017 in Honolulu, Hawaii, where CytoSorbents is one of the main sponsors and will have a prominent booth position to talk to interested parties. The ACVECC conference is held in conjunction with the 46(th) Society of Critical Care Medicine Congress (January 21-25, 2017), where CytoSorbents is also an exhibitor (Booth #606).
Mr. Vincent Capponi, Chief Operating Officer of CytoSorbents stated, "The VetResQ adsorber provides a new and unique treatment for severe inflammation, toxin-mediated disease, and drug intoxication not previously available in the animal health market. VetResQ leverages a similar underlying blood purification technology in our commercialized CytoSorb(R) device that is approved in the European Union and has been used in more than 20,000 human treatments safely. Whether it is the sick thoroughbred racehorse or foal suffering from sepsis or toxic shock syndrome, a dog with acute pancreatitis in terrible pain, a cat after being struck by a car, or a dog poisoned from accidentally eating his owner's pill bottles, the pathophysiology is remarkably similar to what is seen in humans, with a similar lack of available effective therapies. Our target customers are the large academic veterinary hospitals and veterinary practices where services like dialysis are administered. Although this is a specialized niche market, we are providing this product at the request of many animal care providers and pet owners, with the goal of improving clinical outcomes for our most trusted and loved animal companions."
VetResQ is capable of reducing a broad range of excessive inflammatory mediators and toxins that could otherwise cause direct tissue injury or serious systemic inflammation that can rapidly lead to instability, organ failure, and death. Some of the relevant substances VetResQ has been shown to remove include:
-- Excessive pro- and anti-inflammatory cytokines (Sepsis and SIRS -
systemic inflammatory response syndrome)
-- Bacterial toxins such as Toxic shock syndrome toxin, Staph. aureus
alpha-hemolysin, and fungal mycotoxins such as aflatoxin (Sepsis,
infection)
-- Pancreatic enzymes (Severe acute pancreatitis)
-- Bilirubin (Liver failure)
-- Myoglobin (Trauma)
-- Activated complement (Autoimmune diseases)
-- Lipophilic drugs (Accidental drug intoxication)
VetResQ is manufactured in the United States by CytoSorbents Corporation in three different sized cartridges (30mL, 100mL, and 300mL) for the treatment of cats, dogs, horses and animals of comparable size. VetResQ is compatible with standard hemodialysis, continuous renal replacement therapy (CRRT), and hemoperfusion blood pumps. VetResQ is available only for veterinary animal usage and is not for human use.
For more information, please visit www.cytosorbents.com/products/VetResQ. For pricing and to order, please contact Lea Garcia at lgarcia@cytosorbents.com
About CytoSorbents Corporation (NASDAQ: CTSO)
